Publications & Presentations

The publications and presentations listed below serve to demonstrate the experience of the senior management of UNTHSC Pre-Clinical Services in the drug discovery and development industry.

PUBLICATIONS


1)  Murphy, T. M., J. Deitz, P. Petersen, S. Mikels, W. Weiss. 2000. Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis, Antimicrob. Agents and Chemother. 44(11):p3022-3027.

2)  Singh, M., P. Petersen, W. Weiss, F. Kong & M. Greenstein. 2000. Saccharomicins, novel heptadecaglycoside antibiotics produced by Saccharothrix espanaensis : Antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 44: p2154-2159.

3)  Edelstein, P., W. Weiss & M. Edelstein. 2003. In vitro activity of Tigecycline (GAR-936) against Legionella pneumophilia, its pharmacokinetics in guinea pigs and use to treat guinea pigs with L. pneumophilia pneumonia. Antimicrob. Agents Chemother. 47(2):533-540.

4)  Weiss, W., T. Murphy, M. Lynch, J. Frye, A. Buklan, B. Gray, E. Lenoy, S. Mitelman, J. O'Connell, S. Quartucccio & C. Huntley. 2003. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med. Primatology. 32(2):82-88. 

5)  Weiss, W., E. Lenoy, T. Murphy, L. Tardio, P. Burgio, S. Projan, O. Schneewind & L. Alksne. 2004. The effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. J Antimicrob. Chemother. 53:480-486.

6)  Venkatesan, A., A. Agarwal, T. Abe, H. Ushirogochi, I. Yamamura, T. Kumagai, P. Petersen, W. Weiss, E. Lenoy, Y. Yang, D. Shlaes, J. Ryan & T. Mansour. 2004. Novel imidazole substituted 6-methylidene-penems as broad-spectrum b-lactamase inhibitors. Bioorg. Med. Chem. 12:5807-5817. 

7)  Weiss, W., T. Murphy, E. Lenoy & M. Young. 2004.  In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental models of infection. Antimicrob. Agents Chemother. 48(5):1708-1712.

8)  Geneive E. Henry, Smita Raithore, Yanjun Zhang, Bolleddula Jayaprakasam, Muraleedharan G. Nair, David Heber, Navindra P. Seeram. Acylphloroglucinol derivatives from Hypericum prolificum. Journal of Natural Products, 69, 1645-1648, 2006.

9)  Yun Wang, Barbara Christian, Ernestine Mitchell, Bolleddula Jayaprakasam, Muraleedharan G. Nair, Jeffery M. Peters, Julia Busik, L. Karl Olson and Donald B. Jump.  Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. Journal of Lipid Research, 47, 2028-2041, 2006.

10) Weiss, W., P. Petersen, T. Murphy, L. Tardio, Y. Yang, P. Bradford, A. Venkatesan, T. Abe, T. Isoda, A. Mihira, H. Ushirogochi, T. Takasake, S. Projan, J. O'Connell & T. Mansour. 2004. In vitro and in vivo activity of novel 6-methylidene penems as b-lactamase inhibitors. Antimicrob. Agents Chemother. 48(12):4589-4596.

11) Gonzales XF, Deshmukh A, Pulse M, Johnson K, Jones HP. 2008. Stress-induced differences in primary and secondary resistance against bacterial sepsis corresponds with diverse corticotropin releasing hormone receptor expression by pulmonary CD11c+ MHC II+ and CD11c- MHC II+ APCs.  Brain Behav Immun. May;22(4):552-64.

12) Kim IH, Combrink KD, Ma Z, Chapo K, Yan D, Renick P, Morris TW, Pulse M, Simecka JW, and Ding CZ. 2007.  Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins..  Bioorg Med Chem Lett. Mar 1;17(5):1181-4

13) Bao, D., T. Truong, P. Renick, M. Pulse & W. Weiss. 2008. Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 46:723-727.

14) Endimiani, A., K. Hujer, A. Hujer, M. Pulse, W. Weiss & R. Bonomo. 2011. Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(1):82-85.

15) Olson, P., L. Kuechenmeister, K. Anderson, S. Daily, K. Beenken, C. Roux, M. Renierre, T. Lewis, W. Weiss, M. Pulse, P. Nguyen, J. Simecka, J. Morrison, K. Sayood, O. Asojo, M. Smeltzer, P. Dunman. 2011. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular turnover, exhibit antimicrobial activity and attenuate pathogenesis. PLos Pathogens. Vol. 7 (2):e1001287.

16) Parsons, J., M. Kukula, P. Jackson, M. Pulse, J. Simecka, D. Valtierra, W. Weiss, N. Kaplan, C. Rock. 2013. Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252. Antimicrob. Agents Chemother. In press.


ABSTRACTS / PRESENTATIONS

1)  Murphy, T., E. Lenoy, M. Young & W. Weiss. 2002. In vivo efficacy of AC98-6446, a novel glycopeptide, in experimental models of infection. Abstract # F356, 42nd ICAAC, San Diego, CA.

2)  Edelstein, P., W. Weiss & M. Edelstein. 2002. Tigecycline (GAR-936) Activity vs. Legionella In Vitro, and in a Cell and Animal Model of Legionnaires' Disease. Abstract#E-1138. , 42nd ICAAC, San Diego, CA.

3)  Weiss, W., E. Lenoy, T. Murphy, L. Tardio, P. Burgio, S. Projan, O. Schneewind & L. Alksne. 2003. The effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. Abstract#480. 43rd ICAAC, Chicago, IL.

4)  T. Abe, H. Ushirogochi, I. Yamamura, T. Kumangi, T. Mansour, A. Venkatesan, A. Agarwal, P. Petersen, E. Lenoy, W. Weiss, Y. Yang & D. Shlaes. 2003. Novel penems bearing a methylidine linkage as a broad spectrum b-lactamase inhibitor. Abstract#873. 43rd ICAAC, Chicago, IL.

5)  Venkatesan, A., T. Mansour, O. Dos Santos, A. Agarwal, P. Petersen, W. Weiss, Y. Yang, D. Shlaes, T. Abe, H. Ushirogochi, I Yamamura & T. Kumagai. 2004. Novel penems bearing a bicyclic heterocycle on methylidene linkage as broad spectrum b-lactamase inhibitors and their mechanism of action. Abstract#F-320. 44th ICAAC, Washington, DC.

6)  Bao, D., P.  Renick, M. Pulse, T. Truong, T. Morris & W. Weiss. 2005. In vivo evaluation of antimicrobial agents against device related Staphylococcus aureus infections in a mouse subcutaneous implant model. Drug Discovery Technology & Development (IBC), Boston, MA.

7)  Miller, G., D. Beeman, E. Roche, R. England, W. Weiss & T. Morris. 2005. Enhanced drip flow reactors for pharmacodynamic profiling of antibacterials against staphylococcal biofilms. Abstract#1842. 45th ICAAC, Washington, DC.

8)  Renick, P., M. Pulse, E. Roche, D. Beeman, W. Weiss & T. Morris. 2005. Antibacterial Efficacy and Resistance in a Mouse Model of Device Infections Caused by Staphylococcal Biofilms. USC Microbial Biofilm Symposium, Los Angeles, CA.

9)  Pulse, M., P. Renick, W. Weiss, D. Beeman, T. Truong, D. Bao & T. Morris. 2005. A Rat Central Venous Catheter (CVC) Model of Intravascular Device Infections Caused by Staphylococcal Biofilms. USC Microbial Biofilm Symposium, Los Angeles, CA.

10) XF Gonzales, A Deshmukh, S Johnson, ME Pulse, and HP Jones. 2007.  Acute Stress Impairs Acquired Immune Protection against Streptococcus pneumoniae Despite Delayed Lethality During Initial Infection.  ASM-General Meeting.

11) A Odeh, M Pulse, and JW Simecka. 2007.  Alpha-toxin is Important for Biofilm Formation by Staphylococcus aureus. U.N.T.H.S.C., Research Appreciation Day, April.

12) ME Pulse and ME Hart.  2003. The Role of Serin e Protease-Like F (Spl ) on Alpha-Toxin Expression within Staphylococcus aureus. (poster presentation). U.N.T.H.S.C., Research Appreciation Day.

13) Odeh, A., M. Pulse, P. Renick, W. Weiss, T. Morris, K. Overheim & J. Simecka. 2007. The impact of alpha toxin on in vitro and in vivo biofilm development in Staphylococcus aureus. Poster#B-207. 107th ASM General Meeting, Toronto, Canada

14) Pulse, M., P. Nguyen, P. Renick, W. Weiss, T. Morris & J. Simecka. 2007. Host responses impact antibiotic efficacy and resistance in a mouse subcutaneous device infection model caused by Staphylococcus aureus biofilms. Poster#B-304. 107th ASM General Meeting, Toronto, Canada

15) Renick, P., T. Morris, P. Nguyen, M. Pulse & W. J. Weiss. 2007. Efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in rodent models of bacterial infection. Abstract#F2105. 47th ICAAC, Chicago, IL.

16) Weiss, W.J., D. Bao, G. Miller, T. Morris, P. Nguyen, M. Pulse, P. Renick & T. Truong.  2007. Pharmacokinetic and pharmacodynamic studies with CBR-2092, a novel rifamycin-quinolone hybrid antibiotic. Abstract#F2106. 47th ICAAC, Chicago, IL.

17) Xiong, Y., W. Weiss, T. Doyle, G. Abdelsayed & A. Bayer. 2007. Efficacy of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic, and Vancomycin in Experimental Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE). Abstract#F2107. 47th ICAAC, Chicago, IL.

18) Xiong, Y., W. Weiss, T. Doyle, G. Abdelsayed & A. Bayer. 2007. Comparative Efficacy of CBR-2092 and Conventional Rifampin+Quinolone Combinations in Experimental Infective Endocarditis (IE) Caused by a Quinolone-Resistant MRSA (QRMRSA). Abstract#F2108. 47th ICAAC, Chicago, IL.

19)  Weiss, W., B. Hafkin, N. Kaplan, M. Pulse, P. Nguyen. 2008. Efficacy of AFN-1252 and vancomycin in the mouse subcutaneous abscess model with a methicillin resistant S. aureus. Abstract F1-329. 48th ICAAC, Washington, DC.

20) Pulse, M. E., P. Nguyen, W. J. Weiss, J. W. Simecka. 2009. Alpha-toxin expression and host immunity impact disease severity in a mouse subcutaneous abscess model infected with Staphylococcus aureus. Abstract 09-GM-A-3900. ASM General Meeting, Philadelphia, PA.

21) Pulse, M.E., W. J. Weiss, P. Nguyen, J. Pierce, J. Simecka, R. Scott. 2009. Efficacy of PMX30063 in experimental staphylococcal skin and skin structure infection models. Abstract F1-2013. 49th ICAAC, San Francisco, CA.

22) Weiss, W. J., M. E. Pulse, A. Endiminai, K. Hujer, A. Hujer, R. Bonomo. 2009. Efficacy of NXL104 in combination with ceftazidime in murine infection models. Abstract B-1339. 49th ICAAC, San Francisco, CA.

23) Weiss, W. J., M. E. Pulse, P. Nguyen, J. Pierce, J. Simecka, M. Page. 2009. Efficacy of BAL30072 in experimental respiratory tract infections. Abstract F1-1485. 49th ICAAC, San Francisco, CA.

24) Renick, P. J., E. Roche, S. Tetens, D. Telgenhoff, E. Daniels, L. Seal, D. Carson. 2009. A porcine model of MRSA infection in full thickness wounds with reproducible delayed healing. SAWC/WHS meeting, Dallas, TX.

25) Renick, P.J., E. Roche. 2009. A murine model for biofilm infections in partial thickness wounds. SAWC/WHS meeting, Dallas, TX.

26) Pulse, M., P. Nguyen, J. Pierce, P. Renick, W. Weiss, J. Simecka. 2010. Efficacy of topical and systemic antibiotics in a mouse superficial skin infection model with Staphylococcus aureus. Abstract A-2969. ASM General Meeting, San Diego, CA.

27) Landersdorfer, C., W. J. Weiss, A. Forrest, S. Bhavani, M. Pulse, L. Xerri, P. Ambrose. 2010. Razupenem pharmacokinetics-pharmacodynamics, against enterobacteriaceae and S. aureus in a murine thigh and lung infection model. Abstract. 50th ICAAC, Boston, MA.

28) Weiss, W. J., M. E. Pulse, P. Renick, P. Nguyen, J. Simecka, J. Sutcliffe. 2010. Efficacy of fluorocycline TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC. Abstract. 50th ICAAC, Boston, MA.

29) Weiss, W. J., M. E. Pulse, P. Renick, J. Simecka, W. Stubbings, H. Labischinski. 2010. Pharmacokinetics-pharmacodynamics of finafloxacin in the murine thigh infection model with S. aureus and E. coli. Abstract. 50th ICAAC, Boston, MA.

30) Weiss, W. J., B. Hafkin, N. Kaplan, M. E. Pulse, P. Nguyen, P. Renick, J. Simecka. 2010. Oral pharmacokinetics and efficacy of AFN-1252 in a murine septicemia infection model with S. aureus. Abstract. 50th ICAAC, Boston, MA.

31) Pulse, M., P. Nguyen, J. Pierce, P. Renick, W. J. Weiss, J. Simecka. 2010. Efficacy of imipenem and tigecycline in a mouse pneumonia model infected with Acinetobacter baumannii. Abstract. 50th ICAAC, Boston, MA.

32) Pulse, M., W. Weiss, N. Reyes, C. Kostrub, P. Nguyen, P. Renick & J. Simecka. 2010. Efficacy of ACHN-490 in a Murine Urinary Tract Infection Model with Escherichia coli. Abstract #3254, 48th IDSA, Vancouver, Canada.

33) Pulse, M., P. Nguyen, J. Pierce, K. Peterson, D. Valtierra, W. J. Weiss, J. Simecka. 2011. Alpha-toxin neutralization significantly impacts Staphylococcus aureus biofilm formation. Abstract B-065. 51st ICAAC, Chicago, IL.

34) Pulse, M., N. Kaplan, J. parsons, C. Rock, D. Valtierra, W. J. Weiss. 2011. Effects of AFN-1252 on in viro and in vivoStaphylococcus aureus virulence gene expression. Abstract B-1763. 51st ICAAC, Chicago, IL.

35) Weiss, W. J., R. Vickers, M. Pulse, P. Nguyen, P. Renick, J. Simecka. 2011. Efficacy of SMT-19969 and SMT-21829 in a hamster model of Clostridium difficile disease. Abstract B-1195. 51st ICAAC, Chicago, IL.

36) Weiss, W. J., M. Pulse, P. Nguyen, J. Pierce, P. Renick, D. Valtierra, J. Simecka. 2011. Efficacy of Tigecycline and vancomycin in a rat Staphylococcus aureus endocarditis model. Abstract B-063. 51st ICAAC, Chicago, IL.

37) M. E. Pulse, N. Kaplan, J. Parsons, C. O. Rock, M. Kukula, P. Nguyen, J. Pierce, D. Valtierra, W. J. Weiss, J. W. Simecka. 2012. AFN-1252 Alters In Vitro and In Vivo Staphylococcus aureus Gene Expression and Reduces Bacterial Counts in a Mouse Granuloma Infection Model. 22nd ECCMID, London, UK.

38) W. J. Weiss, M. E. Pulse, P. Nguyen, J. Pierce, D. Valtierra, K. Peterson, J. Simecka & W. Stubbings. 2013. In vivo efficacy of the novel monosulfactam BAL30072 alone and in combination with meropenem against clinically important Gram-negative pathogens. 23rd ECCMID, Berlin, Germany.

39) M. E. Pulse, P. Nguyen, J. Peirce, K. Peterson, D. Valtierra, W. J. Weiss, B. Sellman, N. Ulbrandt, S. Krishnan, J. Suzich, W. Blair. 2013. Characterization of the programmed death 1 protein (PD-1) and its ligand (PD-L1) in a murine cecal ligation model of sepsis. 53rd ICAAC, Denver, CO.


INVITED SPEAKER


1)  W. Weiss. Pharmacokinetics and Pharmacodynamics in Drug Discovery.  Superbugs and Superdrugs. SMI Conference 2003, London, UK

2)  M. Pulse.  The Effects of Serine Protease-Like F (SplF) on Alpha-Toxin Expression in Staphylococcus aureus. Texas Wesleyan University, Department of Biology Student Research Presentations, April 2003.

3)  W. Weiss. Integrated platform to optimize agents for biofilm activity; Speaker and chairperson. Superbugs and Superdrugs. SMI Conference 2005, London, UK.

4)  W. Weiss. Device-related infections. Superbugs and Superdrugs. SMI Conference 2007, London, UK.

5)  W. Weiss. Gastro-intestinal Diseases. Superbugs and Superdrugs. SMI Conference 2008, London, UK.

6)  W. Weiss. Helicobacter pylori. Superbugs and Superdrugs. SMI Conference 2009. London, UK.

7)  W. Weiss. Anti-infective drug discovery through outsourcing and collaborations. Anti-Infective Summit 2010, Philadelphia, PA.

8)  W. Weiss. The role of academia in drug discovery and development. Anti-Infective Summit 2011. Philadelphia, PA.

9)  W. Weiss. Infectious disease drug discovery; how and where will the new antibiotics come from? SMI Conference 2011, London, UK.

10) W. Weiss. An Update on Current Issues and Progress in C. difficile Disease (CDAD). SMI Superbugs & Superdrugs - A Focus on Antibacterials, March 4-5, 2013, London, UK.

11) M. Pulse. Dosing clindamycin before or after infection dramatically impacts disease outcome in the hamster Clostridium difficile associated disease model. ICAAC 2013, Denver, CO. 

12)  Research and Development in Neglected Diseases. SMI Superbugs & Superdrugs 2014. London, UK.

This page last updated 26th Jun 2014